[HTML][HTML] A dose finding phase II trial of isatuximab (SAR650984, anti-CD38 mAb) as a single agent in relapsed/refractory multiple myeloma
Abstract Background: Isatuximab (SAR650984) is a humanized IgG1 monoclonal antibody
that binds selectively to a unique epitope on the human CD38 receptor. In the dose
escalation part of the Phase I portion of the trial (NCT01749969), isatuximab≥ 10 mg/kg IV
given every other week (q2w) or 10 mg/kg weekly (qw) induced responses in 6/19 recipients
(ORR 32%). Responses were noted at doses as low as 1 mg/kg q2w. The maximum
tolerated dose (up to 20 mg/kg IV qw) was not reached. The most common treatment …
that binds selectively to a unique epitope on the human CD38 receptor. In the dose
escalation part of the Phase I portion of the trial (NCT01749969), isatuximab≥ 10 mg/kg IV
given every other week (q2w) or 10 mg/kg weekly (qw) induced responses in 6/19 recipients
(ORR 32%). Responses were noted at doses as low as 1 mg/kg q2w. The maximum
tolerated dose (up to 20 mg/kg IV qw) was not reached. The most common treatment …
以上显示的是最相近的搜索结果。 查看全部搜索结果